Champions Oncology (CSBR) Common Equity (2011 - 2026)
Champions Oncology (CSBR) posted quarterly Common Equity of $4.1 million for Q2 2026, up 7.85% year-over-year from $3.8 million in Q2 2025, and down 7.08% quarter-over-quarter from $4.4 million in Q1 2026.
Champions Oncology (CSBR) Common Equity (2011 - 2026) Analysis & Trends
Champions Oncology's Common Equity history runs 16 years deep, the most recent figure standing at $4.1 million for Q2 2026.
- In Q2 2026, Common Equity rose 7.85% year-over-year to $4.1 million; the TTM figure through Apr 2026 stood at $4.1 million (up 7.85% YoY), while the FY2026 annual figure was $4.1 million, up 7.85% from the prior year.
- Common Equity for Q2 2026 stood at $4.1 million, down from $4.4 million in the prior quarter.
- The five-year high for Common Equity was $9.2 million in Q1 2022, with the low at -$2.1 million in Q1 2024.
- The 5-year median for Common Equity is $4.1 million (2025), against an average of $4.0 million.
- The sharpest annual moves came in 2024 and 2025: Common Equity plunged 141.05% in 2024, then soared 1165.66% in 2025.
- Champions Oncology's Common Equity stood at $9.2 million in 2022, then slumped by 98.99% to $93000.0 in 2023, then jumped by 632.26% to $681000.0 in 2024, then surged by 521.29% to $4.2 million in 2025, then decreased by 3.85% to $4.1 million in 2026.
- Business Quant data shows CSBR's Common Equity at $4.1 million in Q2 2026, $4.4 million in Q1 2026, and $4.2 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.35 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 757.49 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.79 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 22.38 Bn |
| 10 | Champions Oncology | 71.17 Mn | 71.17 Mn | 7.03 Mn | 4.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 4.07 Mn |
| Jan 31, 2026 | 4.38 Mn |
| Oct 31, 2025 | 4.23 Mn |
| Jul 31, 2025 | 3.54 Mn |
| Apr 30, 2025 | 3.77 Mn |
| Jan 31, 2025 | 5.47 Mn |
| Oct 31, 2024 | 681,000.00 |
| Jul 31, 2024 | -332,000.00 |
| Apr 30, 2024 | -1.90 Mn |
| Jan 31, 2024 | -2.06 Mn |
| Oct 31, 2023 | 93,000.00 |
| Jul 31, 2023 | 1.90 Mn |
| Apr 30, 2023 | 4.64 Mn |
| Jan 31, 2023 | 7.06 Mn |
| Oct 31, 2022 | 9.17 Mn |
| Jul 31, 2022 | 8.98 Mn |
| Apr 30, 2022 | 9.10 Mn |
| Jan 31, 2022 | 9.24 Mn |
| Oct 31, 2021 | 8.07 Mn |
| Jul 31, 2021 | 7.54 Mn |